{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-006559","form_type":"8-K","ticker":"PROF","cik":"0001628808","company_name":"Profound Medical Corp.","filed_at":"2026-10-09T17:11:55+00:00","discovered_at":"2026-10-09T17:13:03.177716+00:00","generated_at":"2026-10-12T15:14:07.730095+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Profound Medical, Telix sign co-education deal pairing PSMA-PET imaging with TULSA-PRO therapy","bullets":["Co-education agreement pairs Telix's PSMA-PET agents Gozellix and Illuccix with Profound's MRI-guided, incisionless TULSA-PRO platform in prostate care.","Planned initiatives: medical society meetings, KOL programs, educational summits, speaker programs, webinars, clinical case studies and best-practice content.","Profound is developing PSMA-PET-MR image fusion for a planned future Treatment Delivery Console software release; no financial terms were disclosed.","CEO Arun Menawat cites increased access to urologists via Telix; Telix Precision Medicine CEO Kevin Richardson cites more personalized patient care.","CTO Mathieu Burtnyk: ~85% of prostate cancers are multifocal while ~15% are unifocal; ~15-25% of patients are focal-ablation candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-006559","json":"https://secwatch.observer/filing/0001171843-26-006559.json","markdown":"https://secwatch.observer/filing/0001171843-26-006559.md","text":"https://secwatch.observer/filing/0001171843-26-006559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326006559/0001171843-26-006559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628808/000117184326006559/f8k_100926.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:14:07.730095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}